Navigation Links
Jiangbo Pharmaceuticals' Osteomyelitis Treatment Tablets to be Included in China's National Insurance Directory
Date:1/13/2010

LAIYANG, China, Jan. 13 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) (the "Company" or "Jiangbo"), a pharmaceutical company with its principal operations in China, today announced that its Osteomyelitis treatment tablets (Kang Gu Sui Yan Pian) has been included in the 2009 Edition of the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Medicine Directory ("the Directory").

Jiangbo is the exclusive manufacturer of Osteomyelitis treatment tablets in China. This product is used to treat bone and bone marrow inflammations. It's a 100% herb-based traditional Chinese medicine. Most osteomyelitis patients currently use chemical drugs such as antibiotics for treatment which may develop drug resistance if the chemical drugs are taken over a long period of time. Chronic patients are also likely to need surgery which is a less preferable treatment for patients in China. Jiangbo's Osteomyelitis treatment tablets offer an alternative mild treatment and were clinically tested to be effective in treating long term osteomyelitis problems.

The Company has four other products which have been included in the Directory. They are Radix Isatidis Granules, Motherwort Herb Electuary (Yi Mu Cao Gao), Ciprofloxacin Hydrochloride tablets and Paracetamol tablets. Currently, the Company is producing limited quantities of these four products.

"The inclusion of Osteomyelitis treatment tablets in the 2009 Edition Directory is an important accomplishment for our Company," said Mr. Wubo Cao, the Company's Chief Executive Officer. "As its exclusive manufacture, we expect the inclusion of Osteomyelitis treatment tablets in the Directory to drive meaningful sales volume growth in future."

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website ( http://www.jiangbopharma.com ).

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, anticipated sales volume growth of the medicines, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    For more information, please contact:

    Jiangbo Pharmaceuticals, Inc.
     Ms. Elsa Sung, CFO
     Phone: +1-954-727-8435
     Email: elsasung@jiangbo.com
     Web:   http://www.jiangbopharma.com

    CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com

SOURCE Jiangbo Pharmaceuticals, Inc.

RELATED LINKS
http://www.jiangbopharma.com/

'/>"/>

SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
2. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
3. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
4. Oramed Pharmaceuticals Announces Filing of Two Registration Statements
5. Jazz Pharmaceuticals to Present at 2010 J.P. Morgan Healthcare Conference
6. Vion Pharmaceuticals Announces FDA Conclusion
7. VIA Pharmaceuticals Receives Delisting Notification From NASDAQ
8. Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
9. Smith & Nephew Completes Acquisition of the Assets of Nucryst Pharmaceuticals Corp.
10. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
11. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... PUNE, India , February 8, 2016 ... to a new market research report "Ablation Technologies Market ... Application (Csardiovascular, Cancer, Pain Management, Cosmetic Surgery, Ophthalmology, Gynecology) ... report studies the global market over the forecast period ... reach $4.44 Billion by 2020, at CAGR of 10.5% ...
(Date:2/8/2016)... In a historic vote among its members this weekend, the Shinnecock Indian ... facility and dispensary on tribal land near Southampton . ... provider for patients in the state,s Medical Cannabis Program. --> ... patients in the state,s Medical Cannabis Program. --> Tribal ... pursue designation from the State of New York ...
(Date:2/8/2016)... http://www.researchandmarkets.com/research/x6mkjm/knee ) has announced ... Market by Product Type (Primary (Cemented & Cementless), ... Eu-5, Japan, Bric, Turkey, Indonesia - Global Analysis ... offering. --> http://www.researchandmarkets.com/research/x6mkjm/knee ) has ... Devices Market by Product Type (Primary (Cemented & ...
Breaking Medicine Technology:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... Inc., will be speaking on how healthcare companies can use newly released government ... the health of a population and intervene and capture the value they create ...
(Date:2/8/2016)... ... ... According to research by the National Association of Dental ... certified or obtain continuing education. To increase patient awareness of the lack of ... to inform dentists and patients about the possible lack of skills and knowledge ...
(Date:2/7/2016)... ... 2016 , ... HealthSmart Holdings, Inc. announced today the launch ... and information to lower the costs, and increase the impact of their healthcare ... healthcare benefits by as much as 22%:, + Price and quality transparency, ...
(Date:2/6/2016)... ... 06, 2016 , ... US Sports Camps is proud to sponsor the Bay ... together top non-profit leaders, ultimate organizations, and coaches from around the US. The theme ... Disc Program Director of Youth and Education, describes this year YUCC as “an important ...
(Date:2/6/2016)... (PRWEB) , ... February 06, 2016 , ... ... phases of eating disorder treatment helps to reduce the frequency and level of ... the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks ...
Breaking Medicine News(10 mins):